Bristol Myers Squibb says KarXT cuts Alzheimer’s psychosis scores 12.0 points at 12 weeks; preliminary 52-week data show a 5.1-point drop.
On the day the U.S. lost its measles-elimination status, BMS CEO Chris Boerner warned against “policies that don’t” protect the drug ecosystem.
Seeing and hearing things that aren’t really there. Paranoia. Distress. Two daughters share how they managed their mothers’ behavioral changes from Alzheimer’s disease while keeping the core element of their relationship — love — intact.
Bristol-Myers Squibb has quietly turned in a strong share price run over the past few years, helped by fresh data for key therapies and a solid pipeline story. With the stock around US$62.91 at the last close, the real question for you is whether that level is backed up by the cash the business can generate over time. Over the past 3 years the stock has returned about 40.5%, which puts real pressure on the cash flow outlook to justify the step up in market value. Recent trial results for...
Bristol Myers Squibb (BMY) plans to establish a unified research & development organization next year under the current development head. Read more here.
The stock is still attractive trading at 10 times forward earnings.
Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.
Bristol Myers Squibb reports 56-week Camzyos phase 3 data in children with obstructive HCM, showing LVOT improvement after placebo switch. Read more here.
Bristol-Myers Squibb (BMY) is back in the spotlight after the FDA granted accelerated approval for ZENBEXUS in multiple myeloma, along with fresh positive trial updates in lung cancer and multiple sclerosis. Recent moves suggest investors are rewarding this stream of drug updates. The share price is up 4.02% over 1 day, 9.15% over 30 days and 20.07% year to date, while the 1-year total shareholder return of 44.28% points to momentum that has been building rather than fading. Scan how...
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bristol-Myers Squibb reported Q3 2026 revenue of US$13.07b and net income of US$2.16b, beating analyst expectations and prompting higher full-year sales guidance, while EPS guidance was updated after an 11.57% earnings surprise. The firm paired this beat with strong growth portfolio performance, new multiple myeloma approvals, and encouraging late-stage data in oncology and neuroscience, which tightened the link between current cash generation and its next wave of pipeline-driven...
Bristol-Myers Squibb is downgraded to Hold as its current valuation appears optimistic ahead of looming patent cliffs. Read more on BMY stock here.
Bristol Myers Squibb’s adjusted earnings fell 17%, but the company raised its sales outlook. Here’s why the drop reflects a pipeline refill, and what its newer drugs need to deliver next.
This is the newest page. Registered accounts read further back.